Traders Buy Large Volume of Call Options on Chemours (NYSE:CC)

The Chemours Company (NYSE:CC) was the recipient of some unusual options trading activity on Wednesday. Stock traders acquired 21,465 call options on the company. This is an increase of 633% compared to the typical daily volume of 2,930 call options.

Chemours Price Performance

Shares of NYSE:CC opened at $13.46 on Wednesday. The company has a current ratio of 1.81, a quick ratio of 0.98 and a debt-to-equity ratio of 24.25. The stock’s fifty day simple moving average is $13.87 and its two-hundred day simple moving average is $18.19. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The stock has a market cap of $2.03 billion, a PE ratio of -13.20 and a beta of 1.47.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the company earned $0.40 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. As a group, analysts forecast that Chemours will post 0.82 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be issued a dividend of $0.0875 per share. The ex-dividend date is Monday, November 16th. This represents a $0.35 annualized dividend and a yield of 2.6%. Chemours’s payout ratio is -34.31%.

Institutional Investors Weigh In On Chemours

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Chemours during the 2nd quarter worth approximately $34,000. Allworth Financial LP purchased a new position in shares of Chemours in the 2nd quarter worth approximately $51,000. State of Wyoming bought a new position in shares of Chemours in the second quarter valued at approximately $67,000. Nykredit A S bought a new position in shares of Chemours in the second quarter valued at approximately $99,000. Finally, Sterling Capital Management LLC grew its holdings in shares of Chemours by 839.3% in the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after acquiring an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Stronger titanium dioxide pricing and growth in Advanced Performance Materials (APM) partly offset weak Thermal & Specialized Solutions (TSS) volumes in the third quarter. Zacks Q3 earnings report
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers. The suit covers investors who acquired shares from February 20 through August 4, 2026, and alleges that the company misrepresented or failed to disclose weakening Opteon aftermarket demand while reaffirming its 2026 outlook. These are allegations, not established findings; the lead-plaintiff deadline is December 7. The litigation adds legal and reputational risk. Pomerantz class action announcement
• Negative Sentiment: Chemours’ third-quarter EPS of $0.21 fell short of the $0.26 analyst consensus, with weak TSS volumes weighing on results, despite revenue slightly exceeding expectations. Zacks Q3 earnings report
• Negative Sentiment: JPMorgan lowered its price target from $15 to $14 and maintained a Neutral rating, signaling more limited expected upside. JPMorgan rating information

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CC shares. UBS Group decreased their target price on shares of Chemours from $16.00 to $15.00 and set a “neutral” rating for the company in a research report on Wednesday, November 4th. Morgan Stanley set a $18.00 price target on shares of Chemours in a research report on Monday, August 10th. JPMorgan Chase & Co. cut their price target on Chemours from $15.00 to $14.00 and set a “neutral” rating for the company in a research note on Monday. Zacks Research downgraded Chemours from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 4th. Finally, Barclays initiated coverage on Chemours in a report on Monday, October 12th. They set an “equal weight” rating and a $16.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $17.36.

Chemours Company Profile

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.